Christina Coffield, NP
Psychiatric/Mental Health · Spearfish, SDNPI 1083290340
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 24.3% of the total. 2025 is the largest year on record at $1,835, 5.2 times the $355 reported in 2022. Among psychiatric/mental health clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$979
- Alkermes, Inc.$747
- Teva Pharmaceuticals USA, Inc.$500
- Neurocrine Biosciences, Inc.$276
- Axsome Therapeutics, Inc.$250
- plus $840 from 8 others
What the payments were for
- Food & beverage$4,51295%
- Education$2365%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $979 |
| Alkermes, Inc. | 48 | $747 |
| Teva Pharmaceuticals USA, Inc. | 28 | $500 |
| Neurocrine Biosciences, Inc. | 12 | $276 |
| Axsome Therapeutics, Inc. | 16 | $250 |
| Johnson & Johnson | 12 | $242 |
| Lundbeck LLC | 9 | $177 |
| Supernus Pharmaceuticals, Inc. | 7 | $152 |
| Vanda Pharmaceuticals Inc. | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
How this compares
$4,748 in reported general payments places this provider in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 145 | $469,856 |
| VraylarCariprazine Hcl | 214 | $309,315 |
| AustedoDeutetrabenazine | 24 | $243,905 |
| AristadaAripiprazole Lauroxil | 55 | $170,070 |
| RexultiBrexpiprazole | 41 | $80,665 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $56,774 |
| Abilify MaintenaAripiprazole | 13 | $36,409 |
| CaplytaLumateperone Tosylate | 17 | $29,074 |
| Paliperidone ErPaliperidone | 103 | $26,775 |
| SaphrisAsenapine Maleate | 11 | $24,813 |
| TrintellixVortioxetine Hydrobromide | 32 | $23,853 |
| Clozapine | 330 | $21,033 |
| BelsomraSuvorexant | 45 | $19,402 |
| Aripiprazole | 213 | $14,372 |
| DayvigoLemborexant | 23 | $7,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $242 | $469,856145 claims |
| AbbVieVraylar, Saphris | $1,156 | $334,128225 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $500 | $243,90524 claims |
| Alkermes, Inc.Aristada, Lybalvi | $747 | $226,84388 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $51 | $117,07554 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $979 | $29,07417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Spearfish
- Brian BrandtSpearfish$155
- Dione RoweWinner$152K
- Jennifer ErdmanRapid City$6K
- Nichole JohnsonSioux Falls$5K
- Andria PetersenSioux Falls$5K
- Carrie DyllaWatertown$4K
- Josie RiesWatertown$4K
- Holly AhlersSioux Falls$4K
- Jessica KoupalBlackhawk$3K
- Amy NewstromRapid City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.